Improved stability of multivalent antibodies containing the human collagen XV trimerization domain

mAbs

Volumn 4, Issue 2, 2012, Pages 226-232

  Cuesta, Ángel M ^a   Sánchez Martín, David ^a   Blanco Toribio, Ana ^b   Villate, Maider ^c   Enciso Álvarez, Kelly ^a   Alvarez Cienfuegos, Ana ^b   Sainz Pastor, Noelia ^a   Sanz, Laura ^a   Blanco, Francisco J ^c,d   Álvarez Vallina, Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Leadartis SL   (Spain)

^c CIC BIOGUNE   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Antibody engineering; Collagen XV; Collagen XVIII; Multivalent antibody; Tumor targeting

Indexed keywords

COLLAGEN; COLLAGEN 15; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; HYBRID PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ARTICLE; HUMAN; HUMAN CELL; THERMOSTABILITY; ANIMAL; BIOSYNTHESIS; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; MOUSE; NEOPLASM; PATHOLOGY; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODIES, NEOPLASM; COLLAGEN; HEK293 CELLS; HUMANS; MICE; NEOPLASMS; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84858262290     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.2.19140     Document Type: Article

References (33)

1. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; http://dx.doi.org/10.1038/nbt1142.
2. Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005; 26:641-8; PMID:15916728; http://dx.doi.org/10.1111/j.1745-7254.2005.00135.x.
3. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010; 28:355-62; PMID:20447706; http://dx.doi.org/10.1016/j.tibtech.2010.03.007.
4. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444-8; PMID:8341653; http://dx.doi.org/10.1073/pnas.90.14.6444.
5. Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 1999; 231:177-89; PMID:10648937; http://dx.doi.org/10.1016/S0022-1759(99)00157-X.
6. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56:3055-61; PMID:8674062.
7. Sánchez-Arévalo Lobo VJ, Cuesta AM, Sanz L, Compte M, García P, Prieto J, et al. Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer 2006; 119:455-62; PMID:16477626; http://dx.doi.org/10.1002/ijc.21851.
8. Cuesta AM, Sánchez-Martín D, Sanz L, Bonet J, Compte M, Kremer L, et al. In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One 2009; 4:5381; PMID:19401768; http://dx.doi.org/10.1371/journal.pone.0005381.
9. Sánchez-Martín D, Cuesta AM, Fogal V, Ruoslahti E, Alvarez-Vallina L. The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J Biol Chem 2011; 286:5197-203; PMID:21156793; http://dx.doi.org/10.1074/jbc.M110.161927.
10. Pihlajaniemi T, Rehn M. Two new collagen subgroups: membrane-associated collagens and types XV and XVII. Prog Nucleic Acid Res Mol Biol 1995; 50:225-62; PMID:7754035; http://dx.doi.org/10.1016/S0079-6603(08)60816-8.
11. Myers JC, Kivirikko S, Gordon MK, Dion AS, Pihlajaniemi T. Identification of a previously unknown human collagen chain, alpha1(XV), characterized by extensive interruptions in the triple-helical region. Proc Natl Acad Sci USA 1992; 89:10144-8; PMID:1279671; http://dx.doi.org/10.1073/pnas.89.21.10144.
12. Rehn M, Hintikka E, Pihlajaniemi T. Primary structure of the alpha 1 chain of mouse type XVIII collagen, partial structure of the corresponding gene, and comparison of the alpha1(XVIII) chain with its homologue, the alpha1(XV) collagen chain. J Biol Chem 1994; 269:13929-35; PMID:8188673.
13. Rehn M, Pihlajaniemi T. Alpha1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution and homology with type XV collagen. Proc Natl Acad Sci USA 1994; 91:4234-8; PMID:8183894; http://dx.doi.org/10.1073/pnas.91.10.4234.
14. Sasaki T, Fukai N, Mann K, Göhring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998; 17:4249-56; PMID:9687493; http://dx.doi.org/10.1093/emboj/17.15.4249.
15. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000; 301:1179-90; PMID:10966814; http://dx.doi.org/10.1006/jmbi.2000.3996.
16. Boudko SP, Sasaki T, Engel J, Lerch TF, Nix J, Chapman MS, et al. Crystal structure of human collagen XVIII trimerization domain: A novel collagen trimerization Fold. J Mol Biol 2009; 392:787-802; PMID:19631658; http://dx.doi.org/10.1016/j.jmb.2009.07.057.
17. Wirz JA, Boudko SP, Lerch TF, Chapman MS, Bächinger HP. Crystal structure of the human collagen XV trimerization domain: a potent trimerizing unit common to multiplexin collagens. Matrix Biol 2011; 30:9-15; PMID:20932905; http://dx.doi.org/10.1016/j.matbio.2010.09.005.
18. Sanz L, Kristensen P, Blanco B, Facteau S, Russell SJ, Winter G, et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther 2002; 9:1049-53; PMID:12101437; http://dx.doi.org/10.1038/sj.gt.3301725.
19. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single- chain Fv fragment. Cancer Res 1999; 59:5758-67; PMID:10582696.
20. Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol 1990; 1:127-36; PMID:2103489.
21. Denhardt DT, Greenberg AH, Egan SE, Hamilton RT, Wright JA. Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene 1987; 2:55-9; PMID:3438085.
22. Yamashita J, Tashiro K, Yoneda S, Kawahara K, Shirakusa T. Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer. Chest 1996; 109:1328-34; PMID:8625686; http://dx.doi.org/10.1378/chest.109.5.1328.
23. Halfter W, Dong S, Schurer B, Cole GJ. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 1998; 273:25404-12; PMID:9738008; http://dx.doi.org/10.1074/jbc.273.39.25404.
24. Amenta PS, Scivoletti NA, Newman MD, Sciancalepore JP, Li D, Myers JC. Proteoglycan-collagen XV in human tissues is seen linking banded collagen fibers subjacent to the basement membrane. J Histochem Cytochem 2005; 53:165-76; PMID:15684329; http://dx.doi.org/10.1369/jhc.4A6376.2005.
25. Ackley BD, Crew JR, Elamaa H, Pihlajaniemi T, Kuo CJ, Kramer JM. The NC1/endostatin domain of Caenorhabditis elegans type XVIII collagen affects cell migration and axon guidance. J Cell Biol 2001; 152:1219-32; PMID:11257122; http://dx.doi.org/10.1083/jcb.152.6.1219.
26. Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, et al. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci USA 2009; 106:17864-9; PMID:19815504; http://dx.doi.org/10.1073/pnas.0904174106.
27. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996; 26:2304-9; PMID:8898938; http://dx.doi.org/10.1002/eji.1830261006.
28. Sanz L, Kristensen P, Russell SJ, Ramirez García JR, Alvarez-Vallina L. Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother 2001; 50:557-65; PMID:11776378; http://dx.doi.org/10.1007/s00262-001-0235-5.
29. Sanz L, García-Bermejo L, Blanco FJ, Kristensen P, Feijóo M, Suárez E, et al. A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J 2003; 22:1508-17; PMID:12660158; http://dx.doi.org/10.1093/emboj/cdg150.
30. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 2000; 78:1606-19; PMID:10692345; http://dx.doi.org/10.1016/S0006-3495(00)76713-0.
31. Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys J 2002; 82:1096-111; PMID:11806949; http://dx.doi.org/10.1016/S0006-3495(02)75469-6.
32. Laue T. Computer-aided interpretation of analytical sedimentation data for proteins. In: Harding SE, Rowe AJ, Horton JC, Editors. Ultracentrifugation in biochemistry and polymer science. Cambridge: Royal Society of Chemistry 1992; 90-125.
33. Cole JL. Analysis of heterogeneous interactions. Methods Enzymol 2004; 384:212-32; PMID:15081689; http://dx.doi.org/10.1016/S0076-6879(04)84013-8.